Compare IDEXX Laboratories, Inc. (IDXX) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs IAC/Interactivecorp — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while IAC/Interactivecorp trades at $40.21 (market cap $2.97B). The key difference: IDEXX Laboratories, Inc. is far larger — about 15.6× IAC/Interactivecorp's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | PPLI | |
|---|---|---|
Market Cap | $46.22B | $2.97B |
Sector | Health | Media |
52-Week High | $766.68 | $47.62 |
52-Week Low | $526.44 | $31.52 |
Enterprise Value | $47.12B | $3.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
PPLI trades at $40.60, down 0.15% on the day, with a bearish technical signal. Recent Q2 2026 earnings beat expectations at $6.77 EPS, driven by digital growth and MGM investment gains. The company shows strong profitability margins but volatile cash flows, with a net cash outflow of $820.42 million in 2025. Valuation ratios appear attractive with a P/E of 6.76 and P/B of 0.59.
Outlook is mixed: analyst consensus is bullish with a $60.50 price target, but risks include inconsistent earnings, high debt, and negative operating cash flow. The stock offers value potential if turnaround plans succeed, yet faces execution challenges in monetizing non-core assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
